Aarti Drugs Ltd
Aarti Drugs Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #50 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Target volume growth of 8% to 10% annually, with internal ambitions of 10% to 15% growth. - Expect gradual improvement in utilization across newly commissioned facilities, especially methylamine and salicylic acid plants. - Export and regulated market sales to drive growth, with increasing U.S. Management expects gradual improvement in profitability and return ratios in the coming years supported by disciplined execution and operational excellence.
From Aarti Drugs Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Target volume growth of 8% to 10% annually, with internal ambitions of 10% to 15% growth.
- Expect gradual improvement in utilization across newly commissioned facilities, especially methylamine and salicylic acid plants.
- Export and regulated market sales to drive growth, with increasing U.S. FDA and European approvals expected to boost revenues within 12-18 months.
- Formulation business targeted to grow to INR 1,000 crores in the next 3-5 years.
- Price growth expected in antibiotics segment for FY 2027, though volumes may remain flat due to high raw material and crude prices.
2 more points from Aarti Drugs Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Aarti Drugs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Planned capex of INR 300-400 crores over the next 3-4 years focusing on brownfield and quasi-greenfield expansions.
- Capex aimed at increasing existing capacity, especially in formulation business, including an additional block for formulations with EDQM certification.
- Part of the capex directed towards oncology formulations development, which requires significant investment.
- Capex linked to projects such as methylamine, salicylic acid, and formulation R&D including oncology dossiers.
- Potential for increased capex if current greenfield projects (e.g., Sayakha methylamine plant and salicylic acid plant) generate better-than-expected cash flows.
2 more points from Aarti Drugs Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aarti Drugs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- On page 12, it is indicated that formulation capex is partly backed by demand visibility and customer discussions.
- Capacity enhancements are based on forecasts for signed products or products with clear demand visibility once launched.
- R&D capex is typically aligned with products in late-stage development or nearing approval, with most contracts signed near product readiness.
2 more points from Aarti Drugs Ltd's call on order book
Create a free account to keep reading this call
Aarti Drugs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹720 Cr, net profit ₹55 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aarti Drugs Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharmaceuticals Ltd (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals Ltd (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Aarti Drugs Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aarti Drugs Ltd Q4 FY26 results?
Target volume growth of 8% to 10% annually, with internal ambitions of 10% to 15% growth. - Expect gradual improvement in utilization across newly commissioned facilities, especially methylamine and salicylic acid plants. - Export and regulated market sales to drive growth, with increasing U.S. Management expects gradual improvement in profitability and return ratios in the coming years supported by disciplined execution and operational excellence.
What is Aarti Drugs Ltd share price analysis?
Aarti Drugs Ltd currently shows a neutral. The stock trades at a P/E of 19.7 with a market cap of ₹3,800 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aarti Drugs Ltd planning capital expenditure?
Planned capex of INR 300-400 crores over the next 3-4 years focusing on brownfield and quasi-greenfield expansions.
Keep Aarti Drugs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.